AI-generated
May 3, 2026, 10:30
A New Era in Hemophilia A Prophylaxis – NEJM
The New England Journal of Medicine (NEJM) shared a post on X about a recent article by Maria Elisa Mancuso et al., adding:
”Original Article: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors (phase 3 FRONTIER2 trial)
Science behind the Study: A Second Factor VIIIa Mimetic for Hemophilia A.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg

Stay updated on all scientific advances with Hemostasis Today.
Anthony K C Chan
Chandrakala Shanmukhaiah
Chuhl Joo Lyu
Health
Hematology
Hemostasis
Hemostasis News
Hemostasis Today
Ilgiz Rakhmatullin
Joanna Zdziarska
Johannes Oldenburg
Johnny Mahlangu
Lize F.D. van Vulpen
Maria Elisa Mancuso
Medicine
NEJM
Pratima Chowdary
Renchi Yang
Steven R. Lentz
Tadashi Matsushita
Wan Hui Ong Clausen
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM
-
Sep 20, 2026, 00:46Julia R. Coleman: Platelet Biology and Sex Differences in the Plasma Milieu at AAST 2026